Clinical Trials Logo

Leptomeningeal Metastasis clinical trials

View clinical trials related to Leptomeningeal Metastasis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05414123 Terminated - Breast Cancer Clinical Trials

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

FORESEE
Start date: September 7, 2022
Phase:
Study type: Observational

The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose, or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. CNSide, is a Laboratory Developed Test (LDT ) that is used commercially at the Physician's discretion in Biocept's CLIA certified, CAP accredited laboratory. CNSide can detect and quantify tumor cells in the CSF from patients with Breast Cancer or NSCLC having a suspicious or confirmed LM. The goal of the FORESEE Study is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.

NCT ID: NCT04729348 Terminated - Solid Tumor Clinical Trials

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Start date: March 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research is to examine if an experimental drug combination impacts the survival rate of individuals with Leptomeningeal Metastases This research study involves an experimental drug combination. The names of the study drugs involved in this study are: - Pembrolizumab - Lenvatinib